New hope for transplant patients fighting rejection

NCT ID NCT06824103

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the drug ruxolitinib can help control chronic graft-versus-host disease in Chinese patients aged 12 and older when standard steroid treatments have failed. About 50 participants who have had a stem cell transplant will receive ruxolitinib and be followed for up to three years to see if their condition improves and to monitor safety. The goal is to better manage this serious complication where the donor's immune cells attack the recipient's body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Nanning, Guangxi, 530021, China
Novartis Investigative Site
RECRUITING

Guiyang, Guizhou, 550004, China
Novartis Investigative Site
RECRUITING

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site
RECRUITING

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Changsha, 410000, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Shanhecun, 065201, China

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VS. HOST DISEASE CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE GRAFT VS HOST DISEASE